Asthma is a disease characterized by chronic airway inflammation, leading to intermittent
symptoms of wheeze, dyspnea, cough and chest tightness in combination with variable …

Objective: This study sought to characterize the epidemiologic, clinical, humanistic, and
economic burden of patients with asthma uncontrolled by GINA Steps 4 or 5 treatment …

Background There is a lack of tools to quantify the response to monoclonal antibodies
(mAbs) holistically in severe uncontrolled asthma patients. Objective To develop a valid …

El asma grave constituye un síndrome heterogéneo con múltiples variantes clínicas y
representa el último peldaño en la patología asmática en relación con su gravedad. La …

Background Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated
to reduce the risk of severe exacerbations and to improve symptoms, lung function, and …

In the Spanish population, it has been observed that approximately 3.9% of asthmatic 42
patients visiting out-patient hospital clinics have persistent severe uncontrolled asthma 43 …

Optimum treatment of severe asthma represents a major unmet need. Although it affects a
relatively small proportion of the asthma population (approximately 5%-10%), and even less …

Since the publication, 9 years ago, of the latest SEPAR (Spanish Society of Pulmonology
and Thoracic Surgery) Guidelines on Difficult-to-Control Asthma (DCA), much progress has …

Methods Retroprospective, observational, nationwide study using a top-down approach.
Data were obtained from the BIG-PAC®, an electronic medical record database of 1.7 …

Severe asthma (SA) presents in about 3%–5% of adult asthmatics and is responsible for
over 60% of asthma-related medical expenses, posing a heavy socioeconomic burden …